22nd Century Group, Inc. (XXII): Price and Financial Metrics
XXII Price/Volume Stats
Current price | $0.13 | 52-week high | $12.00 |
Prev. close | $0.13 | 52-week low | $0.10 |
Day low | $0.13 | Volume | 2,171,800 |
Day high | $0.14 | Avg. volume | 1,248,243 |
50-day MA | $0.15 | Dividend yield | N/A |
200-day MA | $1.33 | Market Cap | 4.06M |
XXII Stock Price Chart Interactive Chart >
XXII POWR Grades
- XXII scores best on the Value dimension, with a Value rank ahead of 60.42% of US stocks.
- XXII's strongest trending metric is Growth; it's been moving up over the last 122 days.
- XXII's current lowest rank is in the Quality metric (where it is better than 0.25% of US stocks).
XXII Stock Summary
- XXII's price/sales ratio is 0.06; that's higher than the P/S ratio of merely 1.2% of US stocks.
- The volatility of 22ND CENTURY GROUP INC's share price is greater than that of 98.68% US stocks with at least 200 days of trading history.
- 22ND CENTURY GROUP INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -610.81%, greater than the shareholder yield of just 0.72% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to 22ND CENTURY GROUP INC, a group of peers worth examining would be SOI, MTEX, UAVS, UP, and PRLB.
- Visit XXII's SEC page to see the company's official filings. To visit the company's web site, go to www.xxiicentury.com.
XXII Valuation Summary
- XXII's price/sales ratio is 0.1; this is 89.47% lower than that of the median Consumer Defensive stock.
- Over the past 157 months, XXII's EV/EBIT ratio has gone up 210.9.
Below are key valuation metrics over time for XXII.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
XXII | 2023-12-22 | 0.1 | 0.4 | 0 | -0.2 |
XXII | 2023-12-21 | 0.1 | 0.4 | 0 | -0.2 |
XXII | 2023-12-20 | 0.1 | 0.4 | 0 | -0.2 |
XXII | 2023-12-19 | 0.1 | 0.5 | 0 | -0.2 |
XXII | 2023-12-18 | 0.1 | 0.4 | 0 | -0.2 |
XXII | 2023-12-15 | 0.1 | 0.4 | 0 | -0.2 |
XXII Growth Metrics
- Its year over year price growth rate is now at -57.21%.
- The 3 year net income to common stockholders growth rate now stands at -219.42%.
- Its 3 year net cashflow from operations growth rate is now at -38.56%.
The table below shows XXII's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 50.865 | -37.28 | -47.483 |
2022-06-30 | 39.293 | -30.321 | -43.821 |
2022-03-31 | 33.187 | -26.856 | -36.497 |
2021-12-31 | 30.948 | -22.839 | -32.609 |
2021-09-30 | 30.296 | -21.204 | -25.048 |
2021-06-30 | 29.795 | -16.418 | -19.829 |
XXII's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- XXII has a Quality Grade of F, ranking ahead of 0.97% of graded US stocks.
- XXII's asset turnover comes in at 0.448 -- ranking 5th of 5 Tobacco Products stocks.
- MO, TPB, and PM are the stocks whose asset turnover ratios are most correlated with XXII.
The table below shows XXII's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.448 | 0.073 | -0.387 |
2021-03-31 | 0.485 | 0.065 | -0.480 |
2020-12-31 | 0.479 | 0.051 | -0.435 |
2020-09-30 | 0.446 | 0.038 | -0.388 |
2020-06-30 | 0.425 | 0.025 | -0.494 |
2020-03-31 | 0.400 | 0.015 | -0.537 |
XXII Price Target
For more insight on analysts targets of XXII, see our XXII price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $6.33 | Average Broker Recommendation | 1.5 (Moderate Buy) |
22nd Century Group, Inc. (XXII) Company Bio
22nd Century Group, Inc., a plant biotechnology company, provides technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants to be decreased or increased through genetic engineering and plant breeding. The company was founded in 1998 and is based in Clarence, New York.
Latest XXII News From Around the Web
Below are the latest news stories about 22ND CENTURY GROUP INC that investors may wish to consider to help them evaluate XXII as an investment opportunity.
22nd Century Group Completes Sale of Hemp/Cannabis FranchiseSale Will Significantly Reduce Operating Expenses, Ultimately Reduce Debt by $5.2 Million Buffalo, New York--(Newsfile Corp. - December 28, 2023) - 22nd Century Group, Inc. (NASDAQ: XXII) (the "Company" or "22nd Century"), a biotechnology company focused on utilizing advanced plant technologies to improve health and wellness, today announced it has closed the sale of its hemp/cannabis operations. The transaction will significantly reduce the Company's operating costs going forward, a key step in |
22nd Century Group's Senior Lender Approves Sale of Hemp/Cannabis Franchise on Improved TermsSale and Related Actions Ultimately Expected to Reduce Debt Principal by $5.2 Million Buffalo, New York--(Newsfile Corp. - December 14, 2023) - 22nd Century Group, Inc. (NASDAQ: XXII) (the "Company" or "22nd Century"), a biotechnology company focused on utilizing advanced plant technologies to improve health and wellness, today announced it has secured the consent of its senior lender under the terms of its Senior Secured Credit Facility for the previously announced sale of its GVB ... |
22nd Century Secures $3.2 Million to Date in Warrant Exchange TransactionNewly Appointed CEO Leading Restructuring to Focus on Tobacco Industry Operations, Reduce CostsBUFFALO, N.Y., Dec. 04, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) (the “Company”), a biotechnology company focused on utilizing advanced plant technologies to improve health and wellness, today announced the exercise of warrants by certain holders pursuant to its previously announced warrant inducement offering. During the inducement period, certain holders of the Company’s exist |
22nd Century Appoints Larry Firestone as Chairman and CEOTurnaround Veteran to Focus on Unlocking Shareholder Value in Tobacco AssetsBUFFALO, N.Y., Nov. 29, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) (“22nd Century” or the “Company”), a biotechnology company focused on utilizing advanced plant technologies to improve health and wellness, today announced the appointment of Lawrence (Larry) Firestone as the Company's Chairman and Chief Executive Officer. Nora Sullivan, former Chair of the Board, commented, “Larry is a seasoned exec |
22nd Century Group Enters into Agreement to Sell Hemp/Cannabis FranchiseSale Expected to Result in Immediate and Significant Reduction in Operating Costs and Cash RequirementsBUFFALO, N.Y., Nov. 27, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) (the “Company” or “22nd Century”), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness, today announced it has reached an agreement to sell substantially all of its GVB Biopharma (“GVB”) hemp/cannabis operations to Specialty Acquisition Corporation |
XXII Price Returns
1-mo | -7.80% |
3-mo | -30.18% |
6-mo | -86.70% |
1-year | -98.87% |
3-year | -99.70% |
5-year | -99.49% |
YTD | -30.18% |
2023 | -98.65% |
2022 | -70.21% |
2021 | 40.45% |
2020 | 100.00% |
2019 | -55.82% |
Continue Researching XXII
Here are a few links from around the web to help you further your research on 22nd Century Group Inc's stock as an investment opportunity:22nd Century Group Inc (XXII) Stock Price | Nasdaq
22nd Century Group Inc (XXII) Stock Quote, History and News - Yahoo Finance
22nd Century Group Inc (XXII) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...